Price comparison of adagrasib in various countries: where to buy more cost-effectively

Adagrasib (Adagrasib) is used to treat certain types of cancer (non-small cell lung cancer (NSCLC)) that have spread to nearby tissue or other parts of the body, or that cannot be removed by surgery in adults who have received at least one other treatment. Adagrasiib belongs to a class of drugs called KRAS inhibitors, which work by blocking the action of abnormal proteins that signal cancer cells to reproduce, which can help stop or slow the spread of cancer cells. Adagrasib is an irreversible inhibitor of KRAS G12C and belongs to the RAS GTPase family. Oral adagrasib tablets contain 200 mg adagrasib.

The original drug of adagrasib is not yet on the domestic market, so it cannot be included in medical insurance for the time being. It is difficult for domestic patients to obtain this drug through conventional channels. The original research version of adagrasib sold overseas, especially in the U.S. market, is very expensive. A box of 200mg*180 tablets sells for more than 100,000 yuan. This price will also be affected by factors such as exchange rates and will fluctuate, which is undoubtedly a heavy financial burden for patients.

However, new news about this drug has recently appeared in overseas markets. According to reports, the first generic version of adagrasib has been successfully developed and put on the market. The ingredients of this generic drug are highly consistent with the original drug, ensuring the reliability of its efficacy. The manufacturer of this generic drug is Laos Lucius Pharmaceutical Factory, and its price is significantly lower than that of the original drug. The price of a box of 200mg*90 tablets of generic drugs is only over RMB 4,000. Although it is also affected by factors such as exchange rates, overall the price is much more affordable, providing more patients with the possibility of treatment. For more information on overseas drug prices and related information, please consult Yaode Medical Consultant.